Get the Stockscreener App
3.61
46.15%
1.14
After Hours:
3.52
-0.09
-2.49%
Cabaletta Bio Inc stock is traded at $3.61, with a volume of 35.65M.
It is up +46.15% in the last 24 hours and up +54.27% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$2.47
Open:
$2.61
24h Volume:
35.65M
Relative Volume:
10.74
Market Cap:
$330.19M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-2.1747
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
+46.15%
1M Performance:
+54.27%
6M Performance:
+173.48%
1Y Performance:
+1.69%
1-Day Range:
$2.56
$3.67
1-Week Range:
$2.39
$3.67
52-Week Range:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.61 | 225.92M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Will Cabaletta Bio Inc. see short term momentumOil Prices & Weekly Stock Performance Updates - newser.com
Top Biotech Stocks To Follow TodayNovember 1st - MarketBeat
Cabaletta Bio’s Remarkable Surge: Positive Clinical Data and Elevated Price Targets - StocksToTrade
Cabaletta Bio Stock Price Rises After Positive Clinical Data Announcement - timothysykes.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Update - MarketBeat
Tools to assess Cabaletta Bio Inc.’s risk profile2025 Dividend Review & Free Real-Time Market Sentiment Alerts - newser.com
Jennison Associates LLC Boosts Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock? - MSN
Can Cabaletta Bio Inc. stock maintain operating marginsEarnings Growth Summary & Safe Entry Trade Signal Reports - newser.com
Can Cabaletta Bio Inc. hit a new high this monthJuly 2025 Trends & Consistent Profit Trade Alerts - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025Trade Entry Report & Verified Swing Trading Watchlist - newser.com
Cabaletta Bio Stock Climbs Amid Positive Clinical Developments - StocksToTrade
Cabaletta Bio Poised for Growth Amid Positive Clinical Data Releases - timothysykes.com
Cabaletta Bio (NASDAQ:CABA) Price Target Raised to $30.00 - MarketBeat
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.Weekly Trade Summary & Stepwise Entry and Exit Trade Signals - newser.com
CABA Stock: Cantor Fitzgerald Raises Price Target to $30, Mainta - GuruFocus
How Cabaletta Bio Inc. stock reacts to bond yieldsJuly 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Comparing Cabaletta Bio Inc. in custom built stock radars2025 Market Trends & Scalable Portfolio Growth Methods - newser.com
Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials - Insider Monkey
Is Cabaletta Bio Inc. stock attractive for long term wealth buildingEarnings Miss & Consistent Profit Trading Strategies - newser.com
Is Cabaletta Bio Inc. stock attractive for ETFsJuly 2025 Update & Safe Entry Point Alerts - newser.com
Applying sector rotation models to Cabaletta Bio Inc.July 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
10 Best Stocks Under $3 to Invest In - Insider Monkey
Visualizing Cabaletta Bio Inc. stock with heatmaps2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Cabaletta Bio Updates on CD19-CAR T Therapy Progress - TipRanks
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
How Cabaletta Bio Inc. stock benefits from strong dollarPortfolio Gains Summary & Reliable Trade Execution Plans - fcp.pa.gov.br
Cabaletta’s CAR T Therapy Spurs Remissions in Small Lupus Trial - BioSpace
Cabaletta Bio stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Philippines
How Cabaletta Bio Inc. stock compares to growth peers2025 Technical Patterns & AI Powered Market Entry Strategies - fcp.pa.gov.br
What makes Cabaletta Bio Inc. stock attractive to growth fundsDollar Strength & High Accuracy Trade Alerts - fcp.pa.gov.br
Entry Recap: Can Cabaletta Bio Inc. stock rebound after recent weaknessJuly 2025 Institutional & Technical Buy Zone Confirmations - fcp.pa.gov.br
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):